Create Account

One Health helps you track and understand your health simply.

Create Account

One Health helps you track and understand your health simply.

Factor IX

Coagulation

Christmas factorCoagulation factor IX activityFIX

Review status

Currently under review

Pending specialist review and validation.

What it shows

Factor IX is a protein in your blood that helps your body form stable clots after injury. The test measures the functional activity of factor IX in your plasma using a clot-based method, which reflects how well the protein works rather than just how much of it is present. Factor IX is made in the liver and depends on vitamin K to function as part of the intrinsic clotting pathway.

This test is commonly used to evaluate unexplained bleeding or bruising, to investigate an abnormal clotting screen, or to confirm and monitor hemophilia B, a condition caused by low factor IX activity.

Why it matters

Too little working factor IX increases the risk of bleeding into joints or muscles and prolonged bleeding with injuries or procedures, and is the hallmark of hemophilia B. Activity can also fall with vitamin K deficiency, liver disease, or use of medicines that block vitamin K–dependent clotting factor production.

Your clinician may order this test if you have bleeding symptoms, a family history of hemophilia B, or an abnormal screening test before surgery. Results help guide treatment choices, such as the need for factor replacement, vitamin K, or other therapies, and can be used to monitor how well treatment is working.

Understanding your results

If your factor IX activity is lower than expected, your clinician will consider inherited deficiency, acquired causes such as medications, liver problems, vitamin K status, or the presence of an inhibitor that blocks factor IX. Follow-up may include repeating the test with careful sample handling, mixing studies, checking other clotting factors, and screening for inhibitors or genetic testing when appropriate.

If your activity is higher than expected, it can reflect recent factor replacement therapy, physiological changes such as pregnancy, or an acute phase response. Interpretation always depends on your symptoms, medications, and overall clinical context. Do not change or stop any treatment without medical advice, and discuss any concerns with your care team.

A single result rarely provides the full picture. Your provider will integrate this test with your history and other laboratory studies, such as clotting times, and may refer you to a hematology specialist if needed.

Reference ranges

0.351.5 U/mL
All sexes
0 days – 1 month
0.51.5 U/mL
All sexes
0 days – 150 years
0.51.5 U/mL
All sexes
1 month – 150 years

Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.

Factors that could impact Factor IX

  • Tube fill and handling

    Citrate tubes must be filled to the mark and mixed gently. Underfilling or a very high hematocrit can distort the blood-to-anticoagulant ratio and falsely lower activity. Prompt processing and proper freezing reduce degradation.

  • Anticoagulant medications

    Vitamin K antagonists lower factor IX production. Heparin and some direct oral anticoagulants can interfere with clot-based assays. Always tell your care team about all prescription drugs, over-the-counter medicines, and supplements.

  • Liver and vitamin K status

    Because factor IX is made in the liver and requires vitamin K, liver disease, malnutrition, malabsorption, or prolonged antibiotic use can reduce activity and lead to lower results.

  • Recent factor therapy

    Blood drawn soon after infusion of factor IX concentrate or prothrombin complex concentrates can show higher activity. Timing the test relative to your last dose is important for accurate interpretation.

  • Age, pregnancy, and genetics

    Newborns naturally have lower vitamin K–dependent factors, while pregnancy may increase some clotting proteins. Carriers of hemophilia B can have reduced activity and variable bleeding symptoms.

  • Inhibitors and assay interference

    Specific antibodies to factor IX, lupus anticoagulant, or strong acute phase responses can cause unexpected results. Your lab may use mixing studies or chromogenic methods to clarify discrepancies.

2026

References

  1. McGill University Health Centre. (2015, March 01). Factor IX (Task CD 702237). Laboratory reference ranges.
  2. McGill University Health Centre. (2016, March 17). Factor IX (Task CD 18461613). Laboratory reference ranges.
  3. World Federation of Hemophilia. (2020). Guidelines for the management of hemophilia (3rd ed.).
  4. Clinical and Laboratory Standards Institute. (2014). Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays; Approved guideline (5th ed., CLSI document H21-A5).